BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/26/2019 2:56:47 AM | Browse: 688 | Download: 1382
 |
Received |
|
2019-04-24 00:35 |
|
Peer-Review Started |
|
2019-05-08 04:07 |
|
To Make the First Decision |
|
2019-06-03 03:14 |
|
Return for Revision |
|
2019-06-17 03:18 |
|
Revised |
|
2019-06-18 11:29 |
|
Second Decision |
|
2019-07-12 09:59 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-07-20 03:43 |
|
Articles in Press |
|
2019-07-20 03:43 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-08-10 19:11 |
|
Typeset the Manuscript |
|
2019-08-20 06:17 |
|
Publish the Manuscript Online |
|
2019-08-26 02:56 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ozlem Ozer Cakir |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ozlem Ozer Cakir, MD, Assistant Professor, Doctor, Doctor, Department of Gastroenterology and Hepatology, Alanya Alaaddin Keykubat University, School of Medicine, Kestel yerleşkesi, Antalya 07425, Antalya, Türkiye. tansozlem@yahoo.com |
| Key Words |
Anti-tumor necrosis alpha; Refractory pouchitis; Vedolizumab; Ulcerative colitis; ; |
| Core Tip |
Vedolizumab, a humanized immunoglobulin G1 monoclonal antibody to α4β7 integrin, has been shown to moderate gut lymphocyte trafficking with an efficacy in treatment of both Crohn’s disease and ulcerative colitis. In our patient who had two different anti-tumor necrosis factor refractory pouchitis, the gut-specific immune modulation mediated by vedolizumab treatment resulted in good responses. This case is important because of vedolizumab is the novel ttherapy for refractory pouchitis. However, further large and prospective studies are needed for efficacy and the underlying mechanisms of efficacy of vedolizumab in treatment of refractory pouchitis. |
| Publish Date |
2019-08-26 02:56 |
| Citation |
Cakir OO. Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report. World J Clin Cases 2019; 7(16): 2316-2321 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i16/ 2316.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i16.2316 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
